We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ian
Turner-Bone
IAN.TURNER-BONE@liverpoolft.nhs.uk
Dr
Ben
Morton
ben.morton@lstmed.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Other bacterial diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Sepsis is a life-threatening illness caused by a dysregulated immune response to infection. There almost 50 million cases of sepsis per year globally and 11 million sepsis-associated deaths. Early antibiotics for sepsis can improve survival. Doctors, however, currently lack objective criteria on when to commence antibiotics; the choice of agent(s); and when to complete treatment for sepsis. This drives liberal administration of antimicrobials, exacerbating bacterial resistance against antibiotics and harms caused by the drugs themselves (such as severe diarrhoea). Project partners Frequasense Ltd and Liverpool University Hospital Foundation Trust (LUHFT), have developed a test that, in laboratory testing, can rapidly and accurately diagnose bacterial sepsis, from other causes of urgent acute illnesses. If this worked in clinical practice, a rapid and accurate sepsis diagnostic would empower clinicians to administer timely and appropriately antibiotics to patients with sepsis and to withhold potentially harmful antibiotics in patients without infection-related acute illness.
The aim of this study is to recruit adult patients (> = 18 years of age) who present to the accident and emergency department with acute illness (including those with suspected sepsis and those without suspected sepsis) and to take a single blood sample. Those patients will then be followed up to determine their confirmed diagnosis (after clinical investigations and treatment are completed) and outcome (survival to 90 days after admisssion). Final follow up will be by telephone at 90 days. The blood sample will be used to test our device in the laboratory to validate previous studies of diagnostic accuracy. In parallel we will conduct interviews and focus group discussion with key stakeholders including patients, carers and health professionals to explore usefullness and ease of use of a prototype device. The devices and their readings will not be used to influence patient care at any point during this study.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
1. Participant refusal 2. Unclear presumptive diagnosis 3. Prisoners
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Ian
Turner-Bone
IAN.TURNER-BONE@liverpoolft.nhs.uk
Dr
Ben
Morton
ben.morton@lstmed.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by LIVERPOOL SCHOOL OF TROPICAL MEDICINE and funded by Innovate UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53705
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
